Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients with Advanced Solid Tumours

Trial Identifier: D6015C00001
Sponsor: AstraZeneca
NCTID:: NCT02482311
Start Date: July 2015
Primary Completion Date: January 2018
Condition: Ovarian Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
French Translation

Trial Locations

Country Location
Canada, AB Edmonton, AB, Canada, T6G 1Z2
Canada, BC Vancouver, BC, Canada, V5Z 4E6
Canada, ON Toronto, ON, Canada, M5G 2M9
Canada, QC Montreal, QC, Canada, H3T 1E2
United States of America, AR Fayetteville, AR, United States of America, 72703
United States of America, CA La Jolla, CA, United States of America, 92093
United States of America, CA Los Angeles, CA, United States of America, 90048
United States of America, CA San Francisco, CA, United States of America, 94143
United States of America, FL Ft Myers, FL, United States of America, 33905
United States of America, IN Indianapolis, IN, United States of America, 46202
United States of America, MA Boston, MA, United States of America, 02114
United States of America, MA Boston, MA, United States of America, 02215
United States of America, MI Detroit, MI, United States of America, 48201
United States of America, NC Charlotte, NC, United States of America, 28204
United States of America, OH Cleveland, OH, United States of America, 44195
United States of America, OK Oklahoma City, OK, United States of America, 73104
United States of America, PA Philadelphia, PA, United States of America, 19104
United States of America, SC Greenville, SC, United States of America, 29605
United States of America, TN Nashville, TN, United States of America, 37203
United States of America, TX Houston, TX, United States of America, 77030
United States of America, WI Milwaukee, WI, United States of America, 53226